Efficacy of second-line dolutegravir- versus boosted protease inhibitor-based ART in children and adolescents living with HIV at 96 and 144 weeks: pooled analysis of the ODYSSEY and CHAPAS-4 trials

Authors: Amuge P, Jackson C, Bwakura-Dangarembizi M, Kityo C, Lugemwa A, Chabala C, Nyathi M, Nduna B, Musoke P, Yawe I, Kaudha E, Musoro G, Ankunda R, Bbuye D, Violar A, Variava E, Archary M, Cotton M, Cressey RT, Ndebele W, Mulenga V, Mwamabazi M, Szubert A, White E, Walker AS, Elyanu JP, Kekitiinwa RA, Bamford A, Rojo R, Crichton S, Gibb D, Turkova A, Musiime V, Ford D on behalf of the CHAPAS-4 trial, ODYSSEY trial and UNIVERSAL teams

Presented at: International Workshop on HIV and Pediatrics 2025